01. Product portfolioProTransStudy TeamCellaviva
02. About NextCellBusiness ConceptVision, mission, strategyHistory
OrganisationCompany Structure
03. InvestorsTO2 2025 / Rights Issue 2024NextCell as an investmentFinancial CalendarFinancial ReportsCorporate GovernanceCertified AdviserThe ShareArchive
04. NewsPress ReleasesNextCell in the mediaEventsCompany PresentationsQ&A with CEO
05. ContactContact InformationSubscribe
English
/
Svenska

NextCell’s CSO Appointed to the Board of ATMP Sweden

March 28, 2025

NextCell Pharma AB ("NextCell") proudly announces that the company’s Chief Scientific Officer (CSO), Dr. Lindsay Davies, has been appointed to the board of ATMP Sweden. This further reinforces both her role and NextCell’s position as a key player in the development of advanced therapies, both nationally and internationally.

ATMP Sweden is a key organization for the development and implementation of Advanced Therapy Medicinal Products (ATMPs) in Sweden. By bringing together academia, industry, and healthcare, the organization works to strengthen Sweden’s position as a leader in cell and gene therapies. ATMP Sweden serves as a platform for collaboration, knowledge sharing, and strategic development and plays a crucial role in realizing the potential of advanced therapies within the Swedish healthcare system.

Dr. Lindsay Davies is already a well-established voice in the international cell and gene therapy field. She was recently nominated as Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT), highlighting her influence and leadership on a global scale. As an active member of ISCT’s global industry committee, she has championed key issues related to quality and safety in the development of cell and gene therapies (CGT) and has published scientific articles in the society’s journal Cytotherapy.

“Representing NextCell on the board of ATMP Sweden is an honour and a valuable opportunity to contribute to the strategic development of advanced therapies in Sweden. I look forward to working alongside other leading stakeholders in the field to collectively strengthen Sweden’s position in this rapidly growing industry,” says Dr. Lindsay Davies.

NextCell Pharma is already an active player in the ATMP space through the development of ProTrans, a cell therapy candidate currently undergoing Phase II trials for the treatment of type 1 diabetes. With Lindsay Davies now on the board of ATMP Sweden, the company gains further opportunities to contribute to the national strategy for advanced therapies.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.

About NextCell Pharma AB
NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachmentRead full press release on Cision (external link)
2018-06-29
The Data and Safety Monitoring Board approves the usage of high-dose ProTrans in the ongoing clinical trial
Stem cell company NextCell Pharma AB ("NXTCL") announces today that the Data and Safety Monitoring Board for the clinical trial using ProTrans has given its approval for the principal investigator professor Per-Ola Carlsson and NextCell to proceed and treat 3 patients in the high-dose cohort. The treatment of all three patients in the medium-dose cohort with ProTrans has been assessed as safe using a one-month follow-up period. Now NXTCL is now able to recruit patients for the last dose cohort, which is the high-dose cohort. The recruitment of the last dose cohort is expected to take one
Stem cell company NextCell Pharma AB ("NXTCL") announces today that the Data and Safety Monitoring Board for the clinical trial using ProTrans has given its approval for the principal investigator professor Per-Ola Carlsson and NextCell to proceed and treat 3 patients in the high-dose cohort. The...
Read moreRead more
2018-06-28
Extended tissue establishment authorization
The stem cell company NextCell Pharma AB ("NXTCL") was inspected on 7th May 2018 by the Health and Care Inspectorate (IVO), which is the supervisor of tissue establishments. NXTCL has today received the inspection report that authorizes the business to continue without any changes being required. NXTCL acquired the tissue establishment authorization in 2014-11-19. The permit is reviewed every other year in connection with inspection. The operations were inspected 2016-01-20 and now by 2018-05-07, again with a positive outcome. Tissue establishment is an establishment where physical or
The stem cell company NextCell Pharma AB ("NXTCL") was inspected on 7th May 2018 by the Health and Care Inspectorate (IVO), which is the supervisor of tissue establishments. NXTCL has today received the inspection report that authorizes the business to continue without any changes being required....
Read moreRead more
2018-05-18
Six patients now treated with NextCells ProTrans stem cells
NextCell Pharma AB ("NXTCL") announces that an additional three patients have been treated with ProTrans in the ongoing clinical phase I/II trial. In total 6 patients with type 1 diabetes in the low- and medium-dose-cohort have now undergone treatment. The trial performed with NXTCL's drug candidate ProTrans, is divided into two parts, the first part being a dose-escalation phase with 3 + 3 + 3 patients being treated with either a; low, medium or high dose of ProTrans. Now all patients in the low-dose-cohort and the medium-dose-cohort have been treated. After the 1-month follow-up of the
NextCell Pharma AB ("NXTCL") announces that an additional three patients have been treated with ProTrans in the ongoing clinical phase I/II trial. In total 6 patients with type 1 diabetes in the low- and medium-dose-cohort have now undergone treatment. The trial performed with NXTCL's drug candid...
Read moreRead more
2018-04-30
Today NextCell Publishes its half-year report
NextCell Pharma AB ("NEXTCL", "NextCell") today released its half-year report (September 1, 2017 - February 28, 2018) By "NextCell" or "Company" is meant NextCell Pharma AB with organization number 556965-8361. Amount in brackets in the report refers to the corresponding period in the previous year. Note that the Company's fiscal year is September 1 - August 31. First half (2017-09-01 till 2018-02-28)  · Net sales amounted to SEK 391 204 (120 594). · Operating result amounted to SEK -7 524 256 (-4 863 506). · Cash and bank amounted to SEK 9 444 381 (4 124 396).        ·
NextCell Pharma AB ("NEXTCL", "NextCell") today released its half-year report (September 1, 2017 - February 28, 2018) By "NextCell" or "Company" is meant NextCell Pharma AB with organization number 556965-8361. Amount in brackets in the report refers to the corresponding period in the previous ye...
Read moreRead more
2018-04-27
NextCell enters into Memorandum of Agreement with China General Consulting & Investment Co., Ltd.
NextCell Pharma AB ("NextCell") hereby announces that the company has entered a Memorandum of Agreement with China General Consulting & Investment Co., Ltd. (”CGCI”). The purpose of the agreement is to create a base for future co-operation. The agreement includes that the parties should prioritize working together when it comes to stem cell development and China, but is otherwise without claims or obligations and does not affect NextCell financially. NextCell has developed a patented applied for selection algorithm to ensure the selection and production of potent mesenchymal stem cells in
NextCell Pharma AB ("NextCell") hereby announces that the company has entered a Memorandum of Agreement with China General Consulting & Investment Co., Ltd. (”CGCI”). The purpose of the agreement is to create a base for future co-operation. The agreement includes that the parties should prioritiz...
Read moreRead more
2018-03-27
The Data and Safety Monitoring Board approves the usage of medium-dose ProTrans in the ongoing clinical trial.
Stem cell company NextCell Pharma AB ("NXTCL") announces today that the Data and Safety Monitoring Board for the clinical trial using ProTrans has given its approval for the principal investigator professor Per-Ola Carlsson and NextCell to proceed and treat 3 patients in the medium-dose cohort. The Data and Safety Monitoring Boards consists of; Ulf Smith MD, PhD, Professor and Director, Lundberg Laboratory for Diabetes Research, Sahlgrenska Academy and Sahlgrenska University Hospital, Gothenburg; Anders Fasth MD, PhD, Professor of Pediatric Immunology, Sahlgrenska Academy and Chief Physician
Stem cell company NextCell Pharma AB ("NXTCL") announces today that the Data and Safety Monitoring Board for the clinical trial using ProTrans has given its approval for the principal investigator professor Per-Ola Carlsson and NextCell to proceed and treat 3 patients in the medium-dose cohort. T...
Read moreRead more
2018-03-14
An update on NextCell Pharma and Nordic Tech House
NextCell Pharma’s (NXTCL) Board decided on 2018-03-13 to utilize its authorization to implement a targeted issue to Nordic Tech House. NextCell Pharma has identified Nordic Tech House as a strategic partner, which justifies deviation from shareholders’ preferential rights. NextCell Pharma buys services from Nordic Tech House to increase exposure of NextCell Pharma and Cellaviva, both to inform about its development of stem cell therapies and stem cell saving and to optimize the digital messaging for the next 2 years. For its Nordic Tech House is paid with shares in NextCell Pharma AB through
NextCell Pharma’s (NXTCL) Board decided on 2018-03-13 to utilize its authorization to implement a targeted issue to Nordic Tech House. NextCell Pharma has identified Nordic Tech House as a strategic partner, which justifies deviation from shareholders’ preferential rights. NextCell Pharma buys se...
Read moreRead more
2018-03-14
Nordic Tech House to invest in stem cell company NextCell Pharma
NextCell Pharma (NXTCL), traded at AktieTorget, announces that a collaboration with Nordic Tech House has been agreed upon where Nordic Tech House will invest in NXTCL and develop the digital presence of NXTCL and Cellaviva. The two-year agreement means that Nordic Tech House will be responsible for the total digital presence of NXTCL, with a specific focus on the family stem cell saving service that is offered to expectant parents through the Cellaviva trademark. Isabella Löwengrip, one of the co-owners of Nordic Tech House, will as influencer, mother, entrepreneur and investor increase the
NextCell Pharma (NXTCL), traded at AktieTorget, announces that a collaboration with Nordic Tech House has been agreed upon where Nordic Tech House will invest in NXTCL and develop the digital presence of NXTCL and Cellaviva. The two-year agreement means that Nordic Tech House will be responsible ...
Read moreRead more
This website uses cookies in order to improve the user experience. Read more
Preferences
DenyAccept